In recent years, with the continuous research on diabetes, the philosophy of diabetes treatment has changed a lot compared to the traditional treatment model. The prominent conceptual changes are the recommendation of early preventive treatment, the advocacy of applying both primary and secondary medications, the advocacy of early combination medications, the requirement of multiple interventions, and aggressive and comprehensive treatment. The landmark study in China, the Daqing study, still shows a lower risk of diabetes in those who received lifestyle interventions during the 20-year follow-up period after the study ended, and even a trend toward lower cardiovascular morbidity and cumulative mortality. In a study in the United States that applied metformin to the intervention group and the intensive lifestyle group compared to the placebo group, both groups had lower blood glucose levels and maintained a lower risk of diabetes during the 10-year follow-up period, suggesting that intensive lifestyle interventions and phased metformin treatment may reduce the risk of diabetes and improve overall blood glucose level changes in the intervention population over time. Therefore, the 2007 American Diabetes Association consensus on IFG (impaired fasting glucose) and IGT (impaired glucose tolerance) states that lifestyle changes, such as weight loss or moderate intensity exercise, can be made for IFG or IGT, while for prediabetes combined ① <60 years of age; ② body mass index (bmi) ≥35 kg hba1c="">6.0%. A dual approach of lifestyle and pharmacological interventions may be considered for those with any of the above risk factors. The main goal of interventions for patients with prediabetes is not only to lower blood glucose, but also to prevent progression from prediabetes to diabetes and, more importantly, to reduce the occurrence of cardiovascular events. It follows that the common focus of our doctor-patient efforts should be to move the line of defense forward to prevent and treat prediabetes! The traditional treatment model for type 2 diabetes, known as “step therapy”, starts with lifestyle changes (diet and exercise), followed by a single oral hypoglycemic agent, then a combination of drugs if it fails, and finally insulin as a last resort. This step-by-step treatment model is too conservative, which is not conducive to controlling blood glucose as soon as possible and keeping patients in a high glucose state for a long time, which is not conducive to delaying and stopping the occurrence of complications. In addition, the inability of glucose-lowering regimen and too late application of insulin may miss the best time to repair islet function, resulting in an irreversible trend of progressive decline of B-cell function. Early intensive treatment is different from the traditional step therapy, it can bring the following benefits: (1) help improve insulin resistance, protect and restore the function of pancreatic islet B cells to a certain extent, delay or prevent the secondary failure of oral hypoglycemic drugs; (2) can give full play to the complementary effect between different drugs, enhance the efficacy of hypoglycemic therapy, make the positive effect enhanced and side effects reduced; (3) effectively delay and reduce the occurrence and development of chronic (3) effectively delay and reduce the occurrence and development of chronic complications. The 2010 Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes also pointed out that early combination therapy and insulin therapy can be initiated if oral medication does not reach the target within a certain period of time. Therefore, early initiation of intensive treatment and active glycemic control can control long-term hyperglycemia as early as possible, delay the decline of pancreatic β-cell function, prevent macrovascular microvascular complications and cardiovascular and cerebrovascular diseases, and achieve the goal of early intensive lifelong benefits. From “pure blood glucose control” to “comprehensive and smooth achievement”. The three major pathogenic mechanisms of type 2 diabetes can be attributed to different causes (1) Insufficient insulin secretion by pancreatic islet B cells, which is often referred to as islet B cell failure. (2) Decreased sensitivity of peripheral tissues to insulin action, which is often referred to as insulin resistance. (3) Increase in glucagon, the hormone that raises blood glucose. The combined effect of these three causes disturbances in the metabolism of substances such as sugar, fat and protein. These metabolic disorders are the pathophysiological basis for the development of diabetes and its complications and co-morbidities. In recent years, the medical profession has put forward higher requirements for blood glucose control of diabetic patients, not only to reduce fasting and postprandial blood glucose, but also to reduce glycated hemoglobin (HbA1C), which reflects the average blood glucose level, and to reduce the fluctuation of blood glucose, so as to obtain comprehensive blood glucose control and achieve the smooth achievement of all indicators, and to realize the comprehensive protection of heart, brain, eyes and kidneys and other organs.